South San Francisco, United States
Mirvie is revolutionizing the field of pregnancy health with its pioneering approach to predicting complications before they occur. Leveraging RNA messages, the company unveils the underlying biology of pregnancy health, offering crucial insights through a simple blood test. This breakthrough technology provides essential information about the unique biology of a pregnancy, driving transformative changes throughout the process. By harnessing this knowledge, Mirvie seeks to redefine how we anticipate, prevent, and address unexpected pregnancy complications.
Founded in 2018 and based in the United States, Mirvie operates at the intersection of Biotechnology and Health Care, with a clear vision to enhance maternal and fetal health outcomes.
The company recently secured a significant milestone with a $4.60M grant investment on 02 August 2023. This injection of capital attests to the confidence in Mirvie’s groundbreaking approach to pregnancy health. With the implications of this investment, Mirvie can further advance its technology and extend its impact within the health and biotechnology sectors.
